CareDx Inc. (NASDAQ:CDNA) has agreed to sell its Lab Products business to EuroBio Scientific for $170 million in cash, marking a strategic shift toward its higher-growth precision testing and digital solutions segments.
The transaction, approved by both companies’ boards, is expected to close by the end of the third quarter of 2026.
• CareDx stock is at critical resistance. Why is CDNA stock breaking out?
Strategic Shift Toward Core Testing Services
John Hanna, president and CEO of CareDx, said the divestiture aligns with the company’s focus on its core Testing Services and Patient and Digital Solutions businesses, which posted strong year-over-year growth in the first quarter.
Testing Services revenue rose 48%, while Patient and Digital Solutions grew 33%, reflecting what Hanna described as a successful “solutions-selling strategy.”
The Lab Products …